Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2016

Danial Christina, Sarin Kavita Y, Oro Anthony E, Chang Anne Lynn S

Abstract excerpt

PURPOSE: To assess the tumor response to the smoothened (SMO) inhibitor, sonidegib (LDE225), in patients with an advanced basal cell carcinoma (BCC) resistant to treatment with vismodegib (GDC0449). EXPERIMENTAL DESIGN: Nine patients with an advanced BCC that was previously resistant to treatment with vismodegib were given sonidegib in this investigational, open-label study. Tumor response was determined using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anilides
Share to Biphenyl Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Basal Cell

Share to Neoplasm Staging

Share to Pyridines

Share to Retreatment

Share to Skin Neoplasms

Share to Smoothened Receptor

Source

Open in PubMed Open full text

Identifiers

PMID: 26546616
DOI: 10.1158/1078-0432.CCR-15-1588
PMCID: PMC4794361

Genes

SMO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.PMID 26546616Read ↗

Resistance to SMO Inhibitors in Advanced Basal Cell Carcinoma: A Case Highlighting the Role of Molecular Tumor Profiling.Semantic proximity Read ↗

Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.Semantic proximity Read ↗

Targeting the hedgehog pathway to treat basal cell carcinoma.Semantic proximity Read ↗

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and BeyondSemantic proximity Read ↗

Study protocol: Sonidegib for Nevoid Basal Cell Carcinoma (Gorlin) Syndrome and EADO stage IIb Sporadic BCC, a phase II Study (SIBLINGS TRIAL).EU CT n. 2024-515989-14-00Semantic proximity Read ↗

Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.Semantic proximity Read ↗

Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trialsSemantic proximity Read ↗

Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinomaSemantic proximity Read ↗

A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the LiteratureSemantic proximity Read ↗

Smoothened variants explain the majority of drug resistance in basal cell carcinoma.Semantic proximity Read ↗

Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms InvolvedSemantic proximity Read ↗

Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.